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Brief Communications
Increased Exhalation of Hydrogen Peroxide in Patients 
with Stable and Unstable Chronic Obstructive 
Pulmonaiy Disease
P. N. RICHARD DEKHUIJZEN, KATJA K. H. ABEN, INGRID DEKKER, LEON P. H. J. AARTS, 
PASCAL L. M. L. WlELDERS, CEES L. A. VAN HERWAARDEN, and AALT BAST
Department of Pulmonary Diseases, Academic Hospital Nijmegen; and Department of Pharmacochemistry,
Free University of Amsterdam, the Netherlands
An imbalance between oxidative stress and antioxidative capacity is thought to piay an important role 
in the development and progression of chronic obstructive pulmonary disease (COPD). To assess the 
lung oxidative status in patients with COPD, we studied whether exhaled hydrogen peroxide (H2O2) 
is increased in breath condensate of patients with stable COPD (n = 12, mean FEV1 51% pred) and 
in patients with exacerbated COPD (n = 19, actual FEVi 36% pred) compared with a healthy control 
group (n = 10, FEVi 108% pred). Expired breath condensate during 15 min of tidal breathing was 
collected by cooling. The concentration of H2O2 was measured spectrophotometrically by means of 
horse radish peroxidase-catalyzed oxidation of tetramethylbenzidine. Concentrations of H2O2 (mean ± 
SEM) were significantly elevated at 0.205 ± 0.054 nM in patients with stable COPD compared with 
0.029 ± 0.012 n.M in the control group (p <  0.05) and were further increased to 0.600 ± 0.075 nM 
in patients with acutely exacerbated COPD (p <  0.001 compared with patients with stable COPD). 
Patients with pulmonary infiltrates on chest radiograph showed similar values compared with patients 
without obvious infiltrates. These findings demonstrate that patients with stable COPD exhibit increased 
oxidant production in the airways and that oxidant production increases further during exacerbations. 
D e k h u ijz e n  P N R , A b e n  K K .H , D e k k e r  I, A a r t s  L P H J , W le ld e r s  P L M L , V a n  H e r w a a rd e n  C IA , B a st  
A . In c r e a s e d  e x h a la t io n  o f  h y d r o g e n  p e r o x id e  in  p a t ie n t s  w it h  s t a b le  a n d  u n s t a b le  c h r o n ic  o b ­
s t r u c t iv e  p u lm o n a r y  d is e a s e . am I respir c rit care med 1994,-1 5 4 * 1  3~i<>.
Reactive oxygen-derived species (ROS) have been implicated in 
the pathogenesis and pathophysiology of tobacco smoke-induced 
chronic obstructive pulmonary disease (COPD) (I). This con­
tention is supported by several findings. Cigarette smoke is a rich 
.source of oxidants. Smokers have increased numbers o f  macro­
phages and neutrophils in their alveoli (2), and these cells are 
activated and produce increased amounts o f ROS (3, 4). Oxida­
tive inactivation of methionine residues o f a,-proteinase inhibi­
tor may contribute to the onset and progression of emphysema (5).
Production of ROS is likely to increase further during an acute 
exacerbation because of the accompanying increased numbers 
o f inflammatory cells in the lower airways (6). In addition, alve­
olar macrophages (AM) in smokers with a recent lower respira-
respect, exhalation of hydrogen peroxide (Hz0 2) is o f potential 
interest. Hydrogen peroxide is a harmful ROS because it is rela­
tively stable, it can cross membranes due to its small size and 
its lack of charge, and it can generate the highly reactive hydroxyl 
radical in the presence of superoxide anions and iron (8). Clini­
cally, increased levels o f exhaled H*Oj have been demonstrated 
in children with asthma (9) and in patients with adult respira­
tory distress syndrome and acute hypoxemic respiratory failure 
( 1 0 , 11) .
We hypothesized that an increased oxidative burden in the 
lungs of patients with COPD would be reflected in increased levels 
o f exhaled H 20 2. The present study was undertaken to answer 
two questions: 1) Is the concentration of exhaled Ha0 2 increased
tory tract infection were found to release increased numbers of in patients with stable COPD compared with normal subjects,
ROS (7).
Direct in vivo  evidence o f increased concentrations o f ROS 
in patients with COPD has not been provided, however. In this
and 2) Are levels of exhaled HzOj increased even further during 
exacerbations of COPD?
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METHODS
Subjects. Three groups o f subjects were studied (Tables 1 and 2): nor­
mal control subjects, patients with stable COPD, and patients with acutely 
exacerbated COPD. Normal control subjects (n = 10; mean [± SEM] 
age, 53 ± 4 yr) were never-smokers with no pulmonary disorders and 
no signs of upper or lower respiratory tract infection in the previous
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TABLE 1
CHARACTERISTICS OF PATIENTS WITH STABLE COPD
Patient
. - - | ..I-.._1 | —.. . ..--- 19 . . p f".
Age, sex Smoking* Pao2 (kPa)
* » . ni il ‘i n i f c  .—m ---- •»- » ■ w , •. —
Pac02 (kPa) FEVi (% pred) t H2O2 (ixM)
l 63, M C 9.2 5.8 63 0.000
2 72, M E 8.9 5.6 36 0.196
3 55, M C 8.3 4.8 57 0.157
4 73, M E 6.6 5.8 38 0.052
5 86, M E 7.2 5.2 55 0.210
6 74, M E 9.7 6.3 18 0.052
7 58, M C 9.4 4.8 61 0.000
8 64, F C 8.6 4.6 63 0.151
9 82, F E 6.2 5.8 62 0.571
10 60, M E 10.7 4.0 70 0.212
11 74, M E 9.3 5.7 49 0.512
12 80, F E 8.2 5.3 45 0.345
Mean 70 8.5 5.3 51 0.205
SEM 3 0.4 0.2 4 0.054
. _111-wti- II •[ I I - I Ill IB vvju-^* *■ |.r* ¿ 1«, * 1’ -* »* s^- -..i.«*j..--.tí,»p-« .*%»>..,i' — w.- u .—*'>».. L. -J- ▼- ----'—j-Vv* — m , n rmmá h i ‘ ‘ irf*y*i ■i» ^ v w b w * l,niry«nii». ..i ■—r. ♦¿•f’.r*. ^ i ■ I ■ ■ i*» m  i ^ m i i  wMMfcn "—» i il .............................................. » ■»■ —*
* Smoking: C = current, E ~ ex.
t  FEVi : actual value at the morning of collection o f breath condensate.
3 mo (FEVt 108 ± 6% pred [12]). Patients with COPD were included 
if postbronchodilator FEV, was below 60% pred and/or FEV,/vital ca­
pacity ratio was below 60%. All patients were classified as smokers or 
exsmokers (i.e., discontinuation of smoking for at least 3 mo) based on 
medical history. Exclusion criteria were pulmonary disorders at present 
or in the past possibly contributing to chronic airflow obstruction (e.g., 
tuberculosis, sarcoidosis, bronchiectasis, and asthma), clinical signs of 
bronchial hyperreactivity and/or acute response to an inhaled bronchodi- 
lator of more than 15% of predicted value, chronic airflow obstruction 
without smoking in the past, regular intake of vitamin C and E, and 
treatment with oral or inhaled /V-acetylcysteine. Patients with stable 
COPD (n = 12; mean [±  SEM] age, 70 ±  3 yr; mean FEV,, 51 ±  4% 
pred) were defined as having no increase in symptoms and no exacerba­
tions in the previous 3 mo. They were on maintenance therapy with in­
haled bronchodilators; one used inhaled corticosteroids, and none re­
ceived oral steroids. An exacerbation was defined by an acute deterioration 
of breathlessness, mostly with increased coughing and production of 
purulent sputum, for which additional medication was indicated (in­
haled bronchodilators, oral or intravenous corticosteroids, or antibiot­
ics). In this group, 19 patients were studied (mean [±  SEM] age, 69 ± 
2 yr; FEV, measured within 6 mo before the exacerbation, 49 ± 4% 
pred). Patients with signs of upper respiratory tract infection were ex­
cluded. Measurements in the acute patients were performed on the first 
or second day after consultation at the outpatient clinic or at hospital­
ization. Only patients who sought medical attention within 1 wk after 
the start o f exacerbation symptoms were included in the study. All re­
ceived supplemental oxygen, which was discontinued for at least 30 min 
before the collection of exhaled breath condensate. The study was ap­
proved by the hospital ethics committee; informed consent was obtained 
from all subjects.
Collection o f  expired breath and measurement o f  H30 2. The sam­
ples were collected in the morning, approximately 1 h after inhalation 
of the patient’s own bronchodilator. Current smokers were requested 
to refrain from smoking after midnight. First, FEV, was measured. Sub­
sequently, the participants were breathing through a face mask with a 
two-way valve. The expired air was conducted through a tube with a col­
CHARACTERISTICS
TABLE 
OF PATIENTS
2
WITH EXACERBATED COPD
Patient
V ... .. ---
• .. '.r r . ■ r"* r > v * - s- .  V.|. • 1
Age, sex
isni* .-.sr.— - ,,-r^  V-T-l'““ '1 •“ *rl * -J * -
Systemic steroids Smoking*
• 1 1 ♦ M .1 ‘»rj lA | .*1..
P^O 2 Pacû2 FEVj (% pred) t H2O2
i 65, M X H 6 * 7 5.6 25 0.148
2 75, M X E 8.5 5.7 26 0.276
3 73, M X E 8.2 4.9 55 0.591
4 62, M X E 8.7 4.5 32 0.307
5 72, M E 8.5 5.3 20 i . m
6 59, F c 8.4 4.6 28 0.719
7 83, M X E 8.4 4.9 29 0.559
8 51, F X E 8.8 4.9 46 0.837
9 60, M X E 7.3 6.8 21 0.636
10 82, F X E 8.3 5.7 78 0.343
11 76, M X E 8.9 5.1 23 1.023
12 79, F X E 6.2 5.8 n.m. 0.396
13 70, F X E 6.3 8.4 20 0.761
14 57, M X E 7.1 5.2 22 0.558
15 60, M X E 9.6 5.6 31 0.326
16 76, F X E 7.6 5.3 63 0.329
17 63, M X C 9.7 5.7 29 0.204
18 64, M X E 8.5 5.3 70 1.063
19 74, M X E 7,0 5.6 35 1.208
Mean 69 8.0 5.5 36 0.600
SEM 2 0.2 0.2 4 0.075
* Smoking: C -  current, E = ex,
 ^ FEVi: actual value at the morning of the collection of breath condensate.
% Arterial blood gas obtained after at least 30 minutes o f breathing am bient air. 
n.m, = not measured.
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lecting system which was placed in ice. The collecting system was con­
nected to a 2 ml sterile plastic tube. In this way, approximately 1 ml of 
breath condensate was collected within 15 min of tidal breathing. The 
samples were immediately placed in liquid nitrogen. Measurements of 
H20 2 were performed within 6 h after sample collection, since prelimi­
nary data showed that H20 2 concentrations did not change during this 
period. The method described by Gallati and Pracht was applied (13). 
Briefly, 100 jj.1 of 420 |iM 3',3,5,5'-tetramethylbenzidine (dissolved in 
0.42 M citrate buffer, pH 3.8) and 10 (4,1 of 52.5 U/ml of horseradish 
peroxidase (HRP; Sigma Chemicals) were added to 100 |xl of the con­
densate. The reaction proceeded for 20 min at room temperature. Sub­
sequently, the mixture was acidified to a pH of 1 with 10 |il of 18 N 
sulfuric acid. The reaction product was measured spectrophotometri- 
cally at 450 nm using an automated microplate reader (model EL312; 
Bio-Tek Instruments Inc.), The absorbance is directly proportional to 
the concentration of H20 2. The detection limit was approximately 0.1 
(.iM H20 2. All samples were measured in duplicate; mean values were 
used for subsequent analysis.
Statistical analysis. Data between the three groups were compared 
using one-way analysis of variance followed by Duncan’s multiple range 
test. A Wilcoxon test was performed to test differences between patients 
with or without pulmonary infiltrates. Spearman correlation tests were 
performed to detect a correlation between the concentration of exhaled 
Hi02 and clinical markers of severity of the disease such as FEW and 
Pao2. All values are presented as mean ± SEM; statistical significance 
was assumed at p < 0.05.
8, FEVj 47 ±  6% pred) exhaled 0.269 ± 0.068 (xM (current versus 
exsmokers, p = 0.094). No significant correlations were found 
between the levels of H20 2 and FEY* (r = 0.13) or Pao2 (r =  
0.16) in patients with stable and unstable COPD.
DISCUSSION
This study shows increased H20 2 concentrations in exhaled breath 
condensate in patients with stable COPD, providing direct evi­
dence o f increased production o f ROS in the airways of these 
patients. A further increase was observed in patients with an ex­
acerbation.
Concentrations of H20 2 measured in exhaled breath conden­
sate may be considered as the net result o f production versus 
scavenging o f  H20 2. An increased production of H20 2 may be  
caused by an increased number of lung inflammatory cells and/or 
increased production of H20 2 by these cells (7). An increased 
number of these cells have been found in the lungs of patients 
with stable COPD. Both bronchial lavage and bronchoalveolar 
lavage fluid obtained from smokers with COPD contained more 
neutrophils than found in fluid obtained from healthy nonsmok­
ers (14, 15). Increased numbers of macrophages and T lympho­
cytes were present in the bronchial mucosa of patients with 
chronic bronchitis and airflow obstruction compared with healthy
RESULTS
Normal subjects had the lowest concentration of H 20 2 in breath 
condensate (0.029 ± 0.012 |iM) (Figure 1). No H20 2 was detected 
in 6 of 10 healthy subjects. In contrast, patients with stable COPD  
exhibited an increased concentration o f exhaled H 20 2 (0.205 ±  
0.054 ¡llM, p < 0.05 compared with normal subjects). Hydrogen 
peroxide was not detected in 2 of these 12 subjects. Finally, H 2Oz 
was detected in all samples of the patients with exacerbated 
COPD and was elevated in comparison with patients with stable 
COPD (0.600 ±  0.075 \xM, p < 0.001).
Patients with an exacerbation with pulmonary infiltrates on 
chest radiograph (n = 5) showed similar values compared with 
patients without obvious infiltrates (n = 14) (0.601 ± 0.166 nM 
and 0.599 ± 0.087 |j,M, respectively). In the group of patients 
with stable COPD, those who still smoked (n = 4, FEV, 61 ± 
1% pred) exhaled 0.077 ± 0.044 |o,M, whereas the exsmokers (n =
p < 0.05 p < 0.001
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Figure 7. Individual data for H2 O2 concentrations in breath con­
densate.
nonsmokers (16). Exacerbations of chronic bronchitis inpatients 
with mild COPD (mean FEVi approximately 66% pred) were 
associated with increased numbers of eosinophils, neutrophils, 
and T lymphocytes in the bronchial wall (6).
Indications of increased activation and production of ROS
by these cells have been observed in smokers (3, 4, 7, 17). Bron­
choalveolar lavage fluid from smokers contained increased num­
bers o f AM with higher densities, which produced more superox­
ide anion radicals (17). In addition, AM from smokers with a 
recent lower respiratory tract infection released increased quan­
tities o f  H2O z (7).
The production of ROS may be reduced, at least in vitro, by 
medications such as f}2 sympathomimetic drugs and theophyl­
line (18). Whether this effect also occurs in vivo is unknown. Nat­
ural protection against an increased concentration of H20 2 
is provided by catalase and —of particular importance in the
— glutathione. Only a few studies have addressed the an- 
tioxidative capacity of the lungs of smokers (4,15, 19). Reduced 
activities of superoxide dismutase, glutathione S-transferase, and 
glutathione peroxidase were found in the AM of elderly smokers 
(4). In contrast, enhanced activities o f  superoxide dismutase and 
catalase, but not of glutathione peroxidase, were shown in the 
AM of younger smokers (19). Linden and colleagues (15) demon­
strated an increased concentration of total glutathione (free and 
disulfide bound) in bronchoalveolar lavage fluid obtained from 
patients with COPD who were current smokers. It is unknown 
whether this increase in total glutathione is caused by continued 
smoking or by COPD itself (i.e., also occurring in exsmokers).
In contrast to our findings, Sznajder and colleagues (10) found 
significantly higher concentrations o f exhaled H20 2 in patients 
with acute respiratory failure and pulmonary infiltrates compared 
with those without. These authors also noted that central ner­
vous system involvement in these patients increased exhaled H20 2 
levels compared with those patients without involvement; more­
over, patients with infiltrates and sepsis exhaled higher levels o f  
H 20 2 than those without sepsis. Thus, the differences observed 
in the study by Sznajder and colleagues may not be attributed 
solely to the presence or absence of infiltrates.
The current smokers in the group with stable COPD tended 
to exhale lower concentrations of H 20 2 compared with the ex­
smokers. The number of patients studied, however, was too small 
to make any conclusions about the ef fects of smoking in this 
respect. In addition, bias may have occurred in our separation
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of smokers and exsmokers, which was based solely on medical 
history.
Hydrogen peroxide is produced not only in the lower but also 
in the upper airways. Therefore, patients with clinically suspected 
upper airway infection were excluded from the study in order 
to avoid a major contribution o f these airways to total H 20 2 exha­
lation. Differences in minute ventilation and breathing pattern 
may have occurred among the different groups. This, however, 
was not likely to account for the differences observed in exhaled 
H z0 2 levels, as changes in minute ventilation and breathing pat­
tern did not alter H20 2 exhalation in animal experiments (10).
In conclusion, our data show that increased H20 2 occurs in 
subjects with stable COPD and even more so in patients with 
exacerbated COPD. These data are consistent with the concept 
that ongoing airway inflammation with elevated production of 
ROS increases lung oxidative stress in patients with stable COPD.
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